Department of Surgery, Kochi Prefectural Hata Kenmin Hospital, 3-1Yoshina, Yamanachou, Sukumo, 788-0785, Japan.
Clin J Gastroenterol. 2021 Feb;14(1):288-292. doi: 10.1007/s12328-020-01273-7. Epub 2020 Oct 27.
Lenvatinib is an inhibitor of tyrosine kinases, such as vascular endothelial growth factor receptor and fibroblast growth factor receptor, and was first approved for use in thyroid cancer in 2015 in Japan. Additional approval was given in March 2018 for its use as a first-line treatment for advanced or unresectable hepatocellular carcinoma. Herein, we report a case of pneumothorax during lenvatinib treatment for multiple lung metastases of hepatocellular carcinoma in a 71-year-old man. Although the development of pneumothorax during treatment with anticancer agents for lung metastases is well-known, this is the first report of pneumothorax induced by lenvatinib during treatment for lung metastases of hepatocellular carcinoma.
乐伐替尼是一种酪氨酸激酶抑制剂，如血管内皮生长因子受体和成纤维细胞生长因子受体，于 2015 年在日本首次被批准用于甲状腺癌。2018 年 3 月，它被批准作为晚期或不可切除的肝细胞癌的一线治疗药物。在此，我们报告了一例 71 岁男性肝癌多发肺转移患者在接受乐伐替尼治疗期间发生气胸的病例。尽管在使用针对肺癌转移的抗癌药物治疗期间发生气胸是众所周知的，但这是首例报告乐伐替尼治疗肝细胞癌肺转移期间发生气胸的病例。
